Rome will be the Euro-mediterranean capital of the bioeconomy for a couple of days. The Italian Forum on Industrial Biotechnology and Bioeconomy (IFIB) goes to the Italian capital from 5 to 6 October at the Palazzo Rospigliosi, in front of the House of the President of the Republic.
Global Bioenergies expands in the Netherlands. The French biotech company led by Marc Delcourt signed a contribution agreement with the shareholders of Syngip B.V. to transfer all Syngip shares to Global Bioenergies S.A. The transaction’s completion remains subject to the fulfilment of several suspensive conditions including approval by the shareholders of Global Bioenergies.
“Biotech is becoming increasingly important to the mainstream chemical industry as the demand for more sustainable solutions intensifies. Biotech is especially well-suited to help with some of the industry’s biggest challenges”. To say it – in this exclusive interview with Il Bioeconomista – is Christophe Schilling, founder and CEO of Genomatica, a widely-recognized bioengineering leader for the chemical industry. The San Diego-based biotechnology company develops and licenses bio-based manufacturing processes for the production of intermediate and basic chemicals.
Since being named CEO in May 2009, Christophe Schilling has led Genomatica to widespread recognition as a leader in industrial biotechnology, with a commercialized first process, top-tier licensees, strong investors and an unrivaled string of awards for engineering (Kirkpatrick), science (EPA Presidential Green Chemistry), industry leadership (voted #1 Hottest three years in a row by Biofuels Digest), and company culture (The Scientist as a Best Place to Work). Schilling frequently speaks on industry trends at major conferences and serves as a member of the World Economic Forum Global Agenda Council on Biotechnology.
Interview by Mario Bonaccorso
Danish biotech giant Novozymes last week broke ground for its new innovation campus in Lyngby, close to the Technical University of Denmark and seven kilometers from Novozymes’ headquarters in Bagsværd.
“Scotland has under 10% of the UK population and over 30% of the land mass giving it considerably more capacity for growing biomass as feedstock for the bioeconomy. Scotland has great research capabilities, a strong base of SMEs looking to develop its bio-capabilities and the joined up support of the government with all its agencies in developing this opportunity”. Roger Kilburn, CEO IBioIC (Industrial Biotechnology Innovation Centre) Scotland, talks to Il Bioeconomista. In this long, exclusive interview, he talks about UK and Scottish bioeconomy, the role of industrial biotechnology and Brexit. “The fundamental reasons for developing the bioeconomy – he says – are the positive impact it has on sustainability, the environment and the ability to produce new and improved materials. None of these fundamentals are affected by Brexit”.
Interview by Mario Bonaccorso
Scotland is set to create waves among the global biotechnology arena as its Industrial Biotechnology Innovation Centre (IBioIC) announces over £3 million of investment across six game changing synthetic biology projects including greener skincare products, more sustainable plastics and improvements to personalised medicine therapies.
The bioeconomy is alive and is set to grow. This is the strong message coming from Vicenza, Italy, where last Thursday and Friday was held the sixth edition of IFIB, the Italian Forum on Industrial Biotechnology and Bioeconomy.
About 300 participants. Among them some of the big global companies active in the bioeconomy: Braskem, Dow, Novamont, NatureWorks, Mossi Ghisolfi, Clariant, GFBiochemicals and Carlsberg. Innovative start-ups, universities and research centers, as well as clusters such as Clib2021 (Germany), IAR Pole (France) and Bio-based Delta (Netherlands). And again: OECD, European Investment Bank, German Bioeconomy Council.
“Sustainability – Rafael Cayuela, Chief Economist at Dow Chemical, stated – is a huge technological challenge but also the single largest business opportunity of this generation”.
Everything is ready in Altavilla Vicentina (Vicenza, Italy) to host the Italian Forum on Industrial Biotechnology and Bioeconomy. Taking place on 22-23 September at CUOA Business Center, IFIB 2016 will bring together the European bioeconomy stakeholders, from universities and research centers to big companies.
Everything is ready in Glasgow, Scotland, to host the European Forum for Industrial Biotechnology and Bioeconomy. Taking place on 18-20 October at the Scottish Exhibition and Conference Centre, EFIB 2016 – organised by EuropaBio and Smithers Rapra – will take advantage of the opportunity to increase engagement between policy makers and a broad range of stakeholders connected with the existing biobased value chain, and reach a new network of end users from a range of industries.
Ginkgo Bioworks and Amyris, Inc. announced a new partnership, which will enable the companies to jointly develop products more efficiently and cost effectively, accelerating time to market.
This breakthrough biotech partnership creates clear leadership with a combined offering that has successfully introduced more bio-based products than any other company known in the field. The combined R&D capabilities of Ginkgo and Amyris put both partners at a significant advantage in the industry by leveraging the joint end-to-end technology platform. This partnership is expected to deliver more new cultured ingredients into the global market in the next three years than the total industry has achieved in the last 10 years.